These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 28056301)

  • 1. [Expression of PD-1/PD-L1 in lung adenocarcinoma and correlation with epidermal growth factor receptor mutation status].
    Wang Y; Da JP; Wang XH; Song AP; Chen H; Zhang HL; Chen S; Wang DW
    Zhonghua Bing Li Xue Za Zhi; 2016 Dec; 45(12):854-858. PubMed ID: 28056301
    [No Abstract]   [Full Text] [Related]  

  • 2. mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.
    Han K; Zhang Y
    J Cancer Res Ther; 2019; 15(4):914-920. PubMed ID: 31436252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 expression according to the EGFR status in primary lung adenocarcinoma.
    Takada K; Toyokawa G; Tagawa T; Kohashi K; Shimokawa M; Akamine T; Takamori S; Hirai F; Shoji F; Okamoto T; Oda Y; Maehara Y
    Lung Cancer; 2018 Feb; 116():1-6. PubMed ID: 29413045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Correlation between the Expression of PD-L1 in Pleural Effusion of Lung Adenocarcinoma and the Clinicopathological Features and Molecular Changes].
    Ma H; Jia J; Guo H; Zhao H; Wang C; Zhao L; Sun Y; Li W; Zhang Z
    Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):150-155. PubMed ID: 32209183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.
    Omori S; Kenmotsu H; Abe M; Watanabe R; Sugino T; Kobayashi H; Nakashima K; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Ohde Y; Endo M; Akiyama Y; Nakajima T; Takahashi T
    Int J Clin Oncol; 2018 Dec; 23(6):1052-1059. PubMed ID: 29948239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression of programmed cell death 1 ligand 1 in lung adenocarcinoma is a poor prognostic factor particularly in smokers and wild-type epidermal growth-factor receptor cases.
    Mori S; Motoi N; Ninomiya H; Matsuura Y; Nakao M; Mun M; Okumura S; Nishio M; Morikawa T; Ishikawa Y
    Pathol Int; 2017 Jan; 67(1):37-44. PubMed ID: 27976463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Level of soluble programmed death-1 ligand 1 in peripheral blood of patients with advanced epidermal growth factor receptor mutated lung adenocarcinoma and its clinical implications].
    Zhang LQ; Chen Y; Pan X; Xing YF; Shi MH; Chen YJ
    Zhonghua Yi Xue Za Zhi; 2016 Dec; 96(48):3870-3874. PubMed ID: 28057155
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
    Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
    Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.
    Takada K; Okamoto T; Shoji F; Shimokawa M; Akamine T; Takamori S; Katsura M; Suzuki Y; Fujishita T; Toyokawa G; Morodomi Y; Okano S; Oda Y; Maehara Y
    J Thorac Oncol; 2016 Nov; 11(11):1879-1890. PubMed ID: 27346415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of programmed death-ligand 1 expression in resected lung cancer and its relationship with EGFR mutation.
    Osoegawa A; Abe M; Takumi Y; Hashimoto T; Karashima T; Miyawaki M; Sugio K
    Thorac Cancer; 2023 Aug; 14(24):2467-2472. PubMed ID: 37455369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
    Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL
    J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
    Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
    Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma.
    Isobe K; Kakimoto A; Mikami T; Kaburaki K; Kobayashi H; Yoshizawa T; Nakano Y; Makino T; Otsuka H; Sano G; Sugino K; Sakamoto S; Takai Y; Tochigi N; Iyoda A; Homma S
    Oncol Rep; 2018 Jul; 40(1):331-338. PubMed ID: 29767258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma.
    Kaira K; Shimizu K; Kitahara S; Yajima T; Atsumi J; Kosaka T; Ohtaki Y; Higuchi T; Oyama T; Asao T; Mogi A
    Eur J Cancer; 2018 Sep; 101():181-190. PubMed ID: 30077123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.
    Yoneshima Y; Ijichi K; Anai S; Ota K; Otsubo K; Iwama E; Tanaka K; Oda Y; Nakanishi Y; Okamoto I
    Lung Cancer; 2018 Apr; 118():36-40. PubMed ID: 29572000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed death ligand 1 protein expression is positively correlated with the solid predominant subtype, high MIB-1 labeling index, and p53 expression and negatively correlated with epidermal growth factor receptor mutations in lung adenocarcinoma.
    Yanagawa N; Shiono S; Endo M; Ogata SY; Yamada N; Sugimoto R; Osakabe M; Uesugi N; Sugai T
    Hum Pathol; 2021 Feb; 108():12-21. PubMed ID: 33159965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.
    Song Z; Yu X; Cheng G; Zhang Y
    J Transl Med; 2016 Jun; 14(1):188. PubMed ID: 27342566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung.
    Kim S; Koh J; Kim MY; Kwon D; Go H; Kim YA; Jeon YK; Chung DH
    Hum Pathol; 2016 Dec; 58():7-14. PubMed ID: 27473266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma.
    Cho JH; Jung HA; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
    J Cancer Res Clin Oncol; 2019 May; 145(5):1341-1349. PubMed ID: 30900155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.